Malta - English - Malta Medicines Authority

baxter healthcare limited - sodium chloride; potassium chloride; magnesium chloride hexahydrate; sodium acetate trihydrate; sodium gluconate - solution for infusion - sodium chloride 5.26 g/l; potassium chloride 0.37 g/l; magnesium chloride hexahydrate 0.30 g/l; sodium acetate trihydrate 3.68 g/l; sodium gluconate 5.02 g/l - blood substitutes and perfusion solutions

Malta - English - Malta Medicines Authority

b braun melsungen ag carl-braun-strasse 1, d34212 melsungen, germany - calcium chloride, dihydrate, potassium chloride, malic acid, magnesium chloride, hexahydrate, sodium acetate, trihydrate, sodium chloride - solution for infusion - calcium chloride dihydrate 0.37 g/l potassium chloride 0.3 g/l l-malic acid 0.67 g/l magnesium chloride hexahydrate 0.2 g/l sodium acetate trihydrate 3.27 g/l sodium chloride 6.8 g/l - blood substitutes and perfusion solutions

United States - English - NLM (National Library of Medicine)

fresenius medical care north america - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium lactate (unii: tu7hw0w0qt) (sodium cation - unii:lyr4m0nh37, lactic acid - unii:33x04xa5at), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - unii:q32zn48698) - delflex® is indicated in the treatment of chronic kidney failure in patients being maintained on peritoneal dialysis. none. risk summary delflex solutions consist of electrolytes, lactate, and bicarbonate at physiological levels, and glucose to facilitate ultrafiltration. while there are no adequate and well controlled studies in pregnant women, appropriate administration of delflex with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm. animal reproduction studies have not been conducted with delflex. the estimated background risk of major birth defects and miscarriage for the indicated population are unknown. all pregnancies have a background risk of birth defect, loss or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary the components of delflex solutions are excreted in human milk. appropriate

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698, sodium cation - unii:lyr4m0nh37), sodium gluconate (unii: r6q3791s76) (gluconic acid - unii:r4r8j0q44b, sodium cation - unii:lyr4m0nh37), sodium acetate (unii: 4550k0sc9b) (acetate ion - unii:569dqm74sc, sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - uni - plasma-lyte a injection ph 7.4 (multiple electrolytes injection, type 1, usp) is indicated as a source of water and electrolytes or as an alkalinizing agent. plasma-lyte a injection ph 7.4 (multiple electrolytes injection, type 1, usp) is compatible with blood or blood components. it may be administered prior to or following the infusion of blood through the same administration set (i.e., as a priming solution), added to or infused concurrently with blood components, or used as a diluent in the transfusion of packed erythrocytes. plasma-lyte a injection and 0.9% sodium chloride injection, usp are equally compatible with blood or blood components. none known

United States - English - NLM (National Library of Medicine)

baxter healthcare corporation - dextrose hydrous (unii: lx22yl083g) (dextrose - unii:iy9xdz35w2), sodium chloride (unii: 451w47iq8x) (sodium chloride - unii:451w47iq8x), potassium chloride (unii: 660yq98i10) (potassium chloride - unii:660yq98i10), magnesium chloride (unii: 02f3473h9o) (magnesium chloride - unii:02f3473h9o), sodium gluconate (unii: r6q3791s76) (sodium gluconate - unii:r6q3791s76), sodium acetate (unii: 4550k0sc9b) (sodium acetate - unii:4550k0sc9b) - injection, solution - 5 g in 100 ml - plasma-lyte® 148 and 5% dextrose injection (multiple electrolytes and dextrose injection, type 1, usp) is indicated as a source of water, electrolytes, and calories, or as an alkalinizing agent. solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.

United States - English - NLM (National Library of Medicine)

natural creations, inc. - magnesium carbonate (unii: 0e53j927na) (carbonate ion - unii:7ujq5ope7d), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838), horse chestnut (unii: 3c18l6rjaz) (horse chestnut - unii:3c18l6rjaz), potassium alum (unii: 1l24v9r23s) (aluminum hydroxide - unii:5qb0t2iun0), aluminum oxide (unii: lmi26o6933) (aluminum oxide - unii:lmi26o6933), bryonia alba root (unii: t7j046yi2b) (bryonia alba root - unii:t7j046yi2b), strychnos nux-vomica seed (unii: 269xh13919) (strychnos nux-vomic - uses: temporarily relieves great straining, large, dry, hard, knotty stools, &/or other symptoms of constipation.** uses: temporarily relieves great straining, large, dry, hard, knotty stools, &/or other symptoms of constipation.**

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 1 g in 100 ml - magnesium sulfate in 5% dextrose injection, usp is indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively.  when used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant.  however, other effective drugs are available for this purpose. intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery.

United States - English - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

United States - English - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 500 mg in 1 ml - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. in such cases, the serum magnesium (mg++ ) level is usually below the lower limit of normal (1.5 to 2.5 meq/liter) and the serum calcium (ca++ ) level is normal (4.3 to 5.3 meq/liter) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection, usp is also indicated for the prevention and control of seizures (convulsions) in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

United States - English - NLM (National Library of Medicine)

hospira, inc. - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate heptahydrate 4 g in 50 ml - magnesium sulfate in water for injection is indicated for the prevention and control of seizures in preeclampsia and eclampsia, respectively. when used judiciously it effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. however, other effective drugs are available for this purpose. intravenous magnesium should not be given to mothers with toxemia of pregnancy during the two hours preceding delivery.